If you are looking for a gift, you may want to take a look at VICL. Expecting result for Allovectin(R)
• Top-line results from the company's Phase 3 registration trial of Allovectin(R), previously projected for release in the third quarter of 2013, are now expected to be released in August.
• Following today's scheduled conference call, as described below, and extending until the release of top-line results, the company will enter a self-imposed quiet period during which time company management will not be interacting substantively with the investment community.
This could have a DNDN run. By the way, VICL has no debt and has 70 million cash.
Allovectin would be a monster. by the word monster, I mean billions. You may want to do some research and then read the articles.
Upside, VICL could run up big time easy. There are no Guarantees, but it is worth the risk for me. I also like MACK and would be a buyer here.